Biogen News and Research

RSS
TPP wins $500,000 grant from Biogen Idec to help students start and run own businesses

TPP wins $500,000 grant from Biogen Idec to help students start and run own businesses

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Scientists receive grant from Biogen Idec to study everyday activities in MS using actual reality

Scientists receive grant from Biogen Idec to study everyday activities in MS using actual reality

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Whitehead Institute enters into scientific research collaboration with Biogen Idec

Whitehead Institute enters into scientific research collaboration with Biogen Idec

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

ISIS conducts phase 2 study of ISIS-SMNRx in infants with type I spinal muscular atrophy

ISIS conducts phase 2 study of ISIS-SMNRx in infants with type I spinal muscular atrophy